

## A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults with Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of Urticaria

---

**Exclusion Criteria:**

- prior use of remibrutinib, dupilumab or other BTK inhibitors

### Conditions & Interventions

**Interventions:**

Drug: Dupilumab, Drug: Placebo solution for injection, Drug: Remibrutinib, Drug: Remibrutinib matching placebo

**Conditions:**

Dermatology (Skin, Hair & Nails)

**Keywords:**

Chronic Spontaneous Urticaria

### More Information

**Description:** The purpose of this study is to evaluate the efficacy of remibrutinib in comparison to dupilumab. We want to see which one works better for helping adults who have chronic spontaneous urticaria (CSU) and haven't had relief with use of second-generation antihistamines in treating adult participants who have CSU.

**Study Contact:** Melissa Kelly - kell2061@umn.edu

**Principal Investigator:** Paul Bigliardi

**Phase:** PHASE3

**IRB Number:** STUDY00025930

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfnder@umn.edu](mailto:sfnder@umn.edu) if you have questions or need assistance.